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Inflammatory bowel diseases (IBDs) are chronic relapsing and remitting conditions associated with long-term gut dysfunction resulting from alterations to the enteric nervous system and a loss of enteric neurons 1, 2 . The mechanisms underlying inflammation-induced enteric neuron death are unknown. Here using in vivo models of experimental colitis we report that inflammation causes enteric neuron death by activating a neuronal signaling complex composed of P2X7 receptors (P2X7Rs), pannexin-1 (Panx1) channels, the Asc adaptor protein and caspases. Inhibition of P2X7R, Panx1, Asc or caspase activity prevented inflammation-induced neuron cell death. Preservation of enteric neurons by inhibiting Panx1 in vivo prevented the onset of inflammation-induced colonic motor dysfunction. Panx1 expression was reduced in Crohn's disease but not ulcerative colitis. We conclude that activation of neuronal Panx1 underlies neuron death and the subsequent development of abnormal gut motility in IBD. Targeting Panx1 represents a new neuroprotective strategy to ameliorate the progression of IBD-associated dysmotility.
Numerous gastrointestinal disorders are associated with abnormal motility, leading to severe and debilitating symptoms. Despite the common view that enteric neurodegeneration or functional impairment of neurons underlies dysmotility in these disorders 1, 2 , the causal mechanisms culminating in neuron death are unresolved. Thus, no neuro protective therapeutic strategies exist to preserve gastrointestinal function, and current treatment options are limited to controlling inflammation, frequently leaving patients with chronic gut dysfunction.
Altered purinergic signaling is a key contributing factor to the pathophysiology of IBD. Increased purine release 3, 4 and reduced purine hydrolysis 3, 5 elevate extracellular purine concentrations during inflammation, and purine receptor gene and protein expres sion are dysregulated in affected humans 6, 7 and in animal models 8 . Experimentally increasing extracellular purine concentrations exacer bates colitis 9 , and impaired purine hydrolysis is associated with increased susceptibility to colitis in humans 5 . Constitutively elevated extracellular ATP abundance contributes to cytotoxicity by chroni cally activating P2X7Rs 10-12 , triggering neuronal death in the central nervous system 10, [13] [14] [15] . Because enteric neurons are rapidly lost when inflammation is initiated and this occurs prior to immune cell infil tration 16 , we tested the hypothesis that direct activation of signaling cascades by enteric neuronal P2X7Rs mediates neuronal death during inflammation. We found robust P2X7R immunoreactivity localized to neurons throughout the myenteric plexus of the C57BL/6 mouse colon ( Fig. 1a) and that inflammation induced a rapid loss of enteric neurons in four models of colitis in mice ( Fig. 1b) . We next assessed the neuroprotective effects of inhibiting P2X7Rs during inflamma tion with the antagonist oxidized ATP (oATP; 7.5 mg per kg body weight, administered intraperitoneally (i.p.)). Without oATP, mouse myenteric neuronal density decreased by 32% ± 8% during colitis ( Fig. 1c,d) . Pretreatment with oATP protected against inflammation induced neuron loss ( Fig. 1c,d ) without affecting macroscopic dam age scores or weight loss patterns ( Fig. 1e,f) . Thus, neuronal P2X7Rs are necessary for neurodegeneration during colitis but not for the inflammatory response per se.
Is P2X7R activation sufficient to drive neuron death? When we challenged wholemount preparations of mouse colonic myenteric plexus with the selective P2X7R agonist BzATP (300 µM, 2 h) and assessed neuronal survival, neural packing density was reduced by 34% ± 2% ( Fig. 1g) , closely resembling the in vivo situation. No immune cells were observed in, or adjacent to, myenteric ganglia in histological evaluation of whole mounts ( Supplementary Fig. 1) , ruling out the possibility that BzATPmediated neuron death is secondary to immune cell P2X7R activation.
Cell death in P2X7Rexpressing oocytes depends on coexpres sion with Panx1 (ref. 17) . Inhibiting Panx1 with the selective small peptide inhibitor 10 Panx (100 µM) 18, 19 completely protected against BzATPinduced neuronal death, whereas the scrambled version of the 10 Panx peptide (scPeptide) had no effect ( Fig. 1g) . In cultured macro phages, P2X7R stimulation contributes to cell death by activating multiple caspases 20 and subsequent interleukin1β (IL1β) release 21 . P2X7Rmediated enteric neuron death required caspases but not IL1β, as we were able to prevent neuronal death with the pancaspase inhibitor zVAD(OMe)fmk (zVAD; 80 µM) ( Fig. 1g ), but treatment with the IL1 receptor antagonist (IL1ra; 1,500 ng ml -1 ) was not neuroprotective (Fig. 1g) .
The immunohistochemical distribution of Panx1 in C57BL/6 mouse colon showed localization on the cell bodies and processes of enteric neurons ( Fig. 2a ) but not glia, as evident by the intimate association of glial fibrillary acidic protein (GFAP)immunoreactive glia with Panx1immunoreactive neurons ( Fig. 2a) . Notably, Panx1expressing myenteric neurons also coexpressed P2X7Rs ( Supplementary  Fig. 2) , and we identified 51% as neuronal nitric oxide synthase (nNOS) immunoreactive and 40% as calretinin immunoreactive ( Supplementary Fig. 2 ).
Inhibiting Panx1 with probenecid (177.5 mg per kg body weight, i.p.) 22,23 during 2,4dinitrobenzene sulfonic acid (DNBS)induced colitis in vivo preserved normal neural packing density without modifying the underlying tissue inflammation (Fig. 2) . Daily pro benecid injections also protected against the 24% ± 4% decrease in myenteric neuron packing density in the dextran sulfate sodium (DSS)induced colitis model ( Fig. 2b) , but not the oxazolone model of ulcerative colitis.
In vivo Panx1 opening may contribute to neuron death by activat ing a large protein complex termed the inflammasome 23 . We tested whether inflammasome activation is required for neuron death in vivo using mice deficient in either the adaptor protein Asc (apoptosisassociated speck-like protein containing a CARD; Pycard -/-) or Nlrp3 (nucleotidebinding domain and leucinerich repeat contain ing gene family pyrin domain containing 3; Nlrp3 -/-). Weight loss and macroscopic damage in DNBStreated Pycard -/and Nlrp3 -/mice were similar to those in wildtype mice treated with DNBS ( Fig. 2d,e ). Neural packing density was not significantly different (P > 0.05) between control animals from the various genetic back grounds (data not shown). However, Pycard -/-DNBStreated mice failed to lose enteric neurons whereas enteric neuron density was sig nificantly (P < 0.0001) reduced by 23% ± 3% in Nlrp3 -/-DNBStreated mice (Fig. 2b) . Therefore, P2X7RPanx1-mediated enteric neural death depends on Asc activation of caspases independent of Nlrp3. Indeed, Asc was ubiquitously expressed by enteric neurons in C57BL/6 mice ( Fig. 2c ), but Nlrp3 immunoreactivity was not evident (data not shown).
Panx1 acts as a channel for ATP release from apoptotic cells to recruit phagocytes 24 . Therefore, we tested whether Panx1 opening, activated by P2X7R, stimulates ATP release from enteric neurons by using the highly ATPresponsive enteric glia 25 surrounding enteric neurons as endogenous 'sniffer cells' .
Bath application of the P2X7R agonist BzATP (100 µM) stimu lated Ca 2+ responses in neurons, followed closely (by 6.75 ± 1 s) by Ca 2+ responses in surrounding enteric glia ( Supplementary Fig. 3a,b and Supplementary Video 1). Characteristic of P2X7R response properties, BzATP responses in neurons and glia were potentiated by lowering of extracellular Ca 2+ and Mg 2+ concentrations, unaffected by treatment with tetrodotoxin (1 µM) and blocked by the P2X7R antagonists oATP (100 µM) and A438079 (30 µM) ( Supplementary  Figs. 3 and 4) . Extrinsic nerve fibers do not express P2X7Rs, and neuronal and glial responses to BzATP remained unchanged after specific ablation of sympathetic innervation or in cultured prepara tions devoid of all extrinsic innervation ( Supplementary Fig. 5 ).
In mice, enteric glia respond to ATP through a phospholipase C (PLC) signaling cascade initiated by P2Y1Rs 25, 26 . If glial responses to BzATP are due to ATP release from neurons, then inhibiting either PLC or P2Y1Rs should preferentially block glial responses to BzATP. In support of this hypothesis, the PLC inhibitor U73122 (10 µM) and the P2Y1R antagonist MRS2179 (10 µM) completely blocked glial npg responses to BzATP with no significant inhibitory effect on neurons ( Supplementary Fig. 3e,i) . Similarly, blocking the extracellular con version of neuronally released ATP to ADP (the endogenous ligand for glial P2Y1Rs) by inhibiting ectonucleotidases (POM1 (50 µM)) abolished glial responses without affecting neuronal responses ( Supplementary Fig. 3f,i) . In summary, these data indicate that enteric neurons release ATP following P2X7R stimulation. We next asked whether P2X7Rstimulated ATP release from enteric neurons depends on Panx1. Inhibiting Panx1 with 2 mM probenecid 22, 23 reduced glial responses to BzATP by 50% ± 12% (Supplementary Fig. 3g,i) . The more specific peptide inhibitor 10 Panx (100 µM) significantly (P < 0.0001) inhibited glial responses to BzATP by 46% ± 11% without affecting neural responses ( Supplementary  Fig. 3h,i) . From these results we conclude that P2X7R stimula tion of enteric neurons elicits a direct release of ATP onto glia through Panx1.
Inflammation-induced impairments in inhibitory enteric neuro muscular transmission in the colon may contribute to the longterm alterations in gastrointestinal motility that persist after inflamma tion resolution [27] [28] [29] [30] [31] [32] [33] . In support of this possibility, we found a 35% reduction in nNOSimmunoreactive neurons during experimental colitis in mice and a substantial decrease in nNOSimmunoreactive myenteric neurons in tissue from subjects with Crohn's disease, but no change in subjects with ulcera tive colitis (Fig. 3a-c) . Decreased nitrergic innervation in experimental colitis in mice was associated with a persistent decrease in electrical field stimulation (EFS) elicited colon relaxations and enhanced EFSelicited contractions ( Fig. 3d,e ). Sensitivity to the nitric oxide synthase inhibitor lNAME but not the purinergic receptor antagonist suramin confirmed that the relaxations were nitrergic and not purinergic ( Supplementary  Fig. 6 ). Muscle responsiveness was not altered in these mice, as responses to the muscarinic agonist bethanechol (10 µM) and the nitric oxide donor sodium nitroprusside (100 µM) were unchanged in inflamed colons (Fig. 3f,g) . Panx1 inhibition-mediated neuro protection during colitis preserved both normal colonic relaxations and contractions following colitis (Fig. 3d,e ), suggesting that inhib iting Panx1mediated neuronal death during colitis could be thera peutically useful to preserve functional innervation and control of colonic muscle. IBDs are clinically relapsingremitting conditions, and thera peutic intervention occurs after an initial bout of inflammation. To test the potential clinical relevance of Panx1 inhibition as a thera peutic strategy, we developed a mouse model of recurrent colitis (Supplementary Fig. 7) . After a second bout of colitis, neuron pack ing density decreased by 28% ± 3% in mice treated with saline dur ing the remission period (Fig. 4a) . Probenecid intervention during remission significantly (P < 0.05) improved neuron survival and protected against further neuron loss during recurrent inflamma tory bouts (Fig. 4a) .
To further determine the clinical importance of our findings, we assessed P2X7R and Panx1 expression in fullthickness colon sections from humans with colitis and control subjects. Both myenteric and submucosal neurons in the human colon robustly expressed P2X7Rs (Fig. 4b) and Panx1 ( Fig. 4c-e ). Notably, changes in Panx1 immuno reactivity in tissue from subjects with IBD mirrored those in nNOS immunoreactivity, with a marked loss of Panx1 immunoreactivity in the myenteric plexus from subjects with Crohn's disease and no change in subjects with ulcerative colitis (Fig. 4f) as compared to sections from unaffected individuals. These results suggest that alterations in the Panx1 signaling pathway are involved in the neuronal pathophysiology associated with Crohn's disease. Whether the decreased Panx1 expres sion in individuals with this disease reflects a loss of Panx1expressing neurons or reduced expression and whether these changes are causa tive or reflective of neuronal pathophysiology in IBD requires further investigation. Collectively, our work identifies a crucial mechanism of neuron death in intestinal inflammation that seems to be relevant in Crohn's disease. Our data support a model whereby elevated levels of extracellular ATP chronically activate neuronal P2X7Rs, Panx1 and caspases, leading to preferential loss of nitrergic neurons (Fig. 4g) . We identify Panx1 as a key molecular substrate underlying enteric neural damage that leads to organ dysfunction following colitis, and our find ings demonstrate that Panx1 inhibition protects neurons and preserves npg Human tissue. We obtained fullthickness specimens of normal and diseased human colon after informed consent from three male subjects with active Crohn's disease, three with ulcerative colitis, and five undergoing resection for colon cancer. These studies were approved by the University of Calgary Conjoint Health Research Ethics Board. Unaffected tissues from resection margins of the subjects with colon cancer served as controls. We performed antigen retrieval with sodium citrate (pH 6.0, 80 °C, 30 min) on the Holland's fixatived, paraffin embedded, sections before proceeding with immunohistochemistry.
Induction of colitis.
We induced colitis with dinitrobenzene sulfonic acid (DNBS), ozazolone, and dextran sodium sulfate (DSS) as previously described 35 .
We anesthetized mice with isoflurane, inserted a gavage needle 3 cm into the colon and injected 0.1 ml of a solution containing either 5 mg DNBS or oxazolone dissolved in 50% ethanol, or saline alone for controls. We monitored mice closely and recorded weight loss daily for 48 h before euthanization and scoring macroscopic damage 36 . We induced DSS colitis by adding 3% DSS to drinking water for 8 d. Il10 -/mice spontaneously developed colitis as previously described 34 . We preserved colonic tissue in Zamboni's fixative.
Whole-mount immunohistochemistry. We prepared wholemount prepara tions of the colonic myenteric plexus by removing the mucosa, submucosa and circular muscle by microdissection. We processed the resulting longitudinal muscle myenteric plexus (LMMP) preparations for immunohistochemistry as previously described 25 with the antibodies listed in Supplementary Table 1 . We confirmed antibody specificity by preabsorption with control peptides or in respective knockout mice. In situ P2X7R-stimulated neuron death. We prepared LMMP whole mounts as for Ca 2+ imaging, pinned them flat in Sylgardcoated 35mm dishes, and maintained them in a humid oxygenated chamber at 34 °C. We obtained a total of six LMMPs from each mouse and, of these, incubated two in buffer alone, two with 300 µM BzATP, and two with 300 µM BzATP plus inhibitor for 2 h. We then rinsed tissues with buffer and maintained them in either buffer alone or buffer with inhibitor for an additional 2 h before being fixed with Zamboni's fixative overnight.
Solutions
Contractility studies. We performed colon contractility studies as previously described 38 . For further details, see Supplementary Methods. Data analysis. We acquired images of ganglia with HuC/Dimmunoreactive or nNOSimmunoreactive neurons for counts through the ×20 (PlanNeofluar, 0.5 numerical aperture) objective of an upright epifluorescence microscope (Zeiss Axioplan, Carl Zeiss) equipped with a Retiga 2000R chargecoupled device camera (QImaging) controlled by QCapture Pro 6.0 software (QImaging). We measured ganglionic area and recorded the number of neurons within that area using ImageJ (NIH). We determined neuronal packing density per mouse by averaging counts from a minimum of ten ganglia per mouse except for in situ experiments, where we averaged counts from a minimum of 20 ganglia from two LMMPs from each treatment group per mouse. We obtained confocal images through the ×60 objective (PlanApo N, 1.42 numerical aperture, oil) of an Olympus BX50 Fluoview laser scanning confocal microscope (Olympus).
Statistical analyses.
We present all results as mean ± s.e.m. with statistical differences determined by oneway ANOVA (with Tukey's or NewmanKeuls posthoc test). A P value of <0.05 was considered significant.
Additional methods. Detailed methodology is described in the Supplementary Methods.
